{"product_id":"synlab-bcg-matrix","title":"SYNLAB Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSUNLAB’s BCG Matrix preview highlights where its core diagnostics and lab services currently sit in market growth and share—flagging potential Stars in high-growth molecular testing and Cash Cows in routine lab services, plus areas that may be Dogs or Question Marks. This snapshot guides strategic prioritization but the full BCG Matrix provides quadrant-by-quadrant data, actionable recommendations, and ready-to-use Word and Excel files to steer investment and resource allocation. Purchase the complete report for the detailed analysis you need to act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Molecular and Genetic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemand for personalized medicine and genomic sequencing in Europe is growing ~12–15% CAGR (2021–25), driven by targeted oncology and rare-disease testing.\u003c\/p\u003e\n\u003cp\u003eSYNLAB dominates the high-tech segment with ~20–25% European market share in advanced molecular diagnostics, using its 500+ clinical labs to scale specialized tests that smaller rivals cannot match.\u003c\/p\u003e\n\u003cp\u003eThese services need ongoing R\u0026amp;D spend; SYNLAB invested €110m in R\u0026amp;D in 2024, and such capex is the primary driver of future leadership in diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Telehealth Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNLAB's digital health and telehealth integration sits as a Star: its integrated platforms for results delivery and remote consults hold ~30–40% market share in key EU markets (2024 EMEA diagnostics report) as demand rose 25% YoY after 2020; global telehealth market hit $90B in 2024. Continuous capex—estimated €50–80M annually—remains vital to stay ahead of health‑tech startups and ensure secure hospital-lab data exchange.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe market for early cancer detection and liquid biopsy is growing ~12–18% CAGR globally, driven by aging populations and new screening guidelines; IVD market forecasts show oncology molecular diagnostics reached €6.5bn in 2024. SYNLAB leads with high-sensitivity oncology panels used in pharma trials and clinics, generating mid-single-digit revenue share gains in 2023. To stay a Star, SYNLAB must invest in high-throughput NGS capacity and automation to scale volumes and protect gross margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Clinical Lab Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSYNLAB’s push into Latin America and Southeast Asia targets markets growing 6–10% annually in diagnostics; by 2024 its regional units captured ~40–55% local share in key countries while recurring revenues rose ~18% YoY, positioning them as market leaders despite heavy upfront spend.\u003c\/p\u003e\n\u003cp\u003eThese units required ~€180–€250m cumulative capex 2021–2024 for acquisitions and lab upgrades, driving negative free cash flow early but enabling higher margins as volumes scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: regional diagnostic demand +6–10%\/yr\u003c\/li\u003e\n\u003cli\u003eMarket share: ~40–55% in target countries (2024)\u003c\/li\u003e\n\u003cli\u003eCapex: ~€180–€250m (2021–2024)\u003c\/li\u003e\n\u003cli\u003eRecurring revenue growth: ~18% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Testing Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDirect-to-consumer testing portals: proactive health monitoring drove a 2024 US retail lab market CAGR ~18% (2021–24), and SYNLAB captured notable share in Europe with retail revenues up ~22% YoY in 2024, outpacing its B2B segments.\u003c\/p\u003e\n\u003cp\u003eGrowth needs sustained high marketing spend—customer acquisition costs rose ~35% in 2023–24—and UI\/UX investments to lower churn; conversion lifts of 8–12% follow modern portal redesigns within 3–6 months.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRetail lab CAGR ~18% (2021–24)\u003c\/li\u003e\n\u003cli\u003eSYNLAB retail rev +22% YoY 2024\u003c\/li\u003e\n\u003cli\u003eCAC up ~35% (2023–24)\u003c\/li\u003e\n\u003cli\u003eRedesigns boost conversion 8–12% in 3–6 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNLAB: Rapid 12–18% CAGR growth, EU leader with 20–55% share and strong retail momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSYNLAB Stars: high-growth molecular diagnostics, digital health, and retail testing showing 12–18% CAGR, 20–55% market shares in EU\/target markets, €110m R\u0026amp;D and €180–250m capex (2021–24), retail rev +22% YoY (2024) and CAC +35% (2023–24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e20–55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€110m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex (2021–24)\u003c\/td\u003e\n\u003ctd\u003e€180–250m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail rev growth\u003c\/td\u003e\n\u003ctd\u003e+22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAC change\u003c\/td\u003e\n\u003ctd\u003e+35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of SYNLAB’s units with clear Star\/Cash Cow\/Question Mark\/Dog guidance and investment, risk, and trend insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page SYNLAB BCG Matrix placing each business unit in a quadrant for quick strategic prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Clinical Chemistry and Hematology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoutine clinical chemistry and hematology — standard blood and urine tests — are SYNLAB’s backbone, generating roughly 40–45% of group revenue and operating in a stable, low-growth market (European market annual volume growth ~1–2% in 2024).\u003c\/p\u003e\n\u003cp\u003eHigh automation (over 70% lab automation in core markets) and fixed-cost leverage deliver gross margins above 60% and strong cash conversion, needing minimal capex to sustain volumes.\u003c\/p\u003e\n\u003cp\u003eCash from these services funded 35–50% of Group capex and M\u0026amp;A for Stars and Question Marks in 2023–24, making them the primary internal financing source.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Hospital Outsourcing Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNLAB's European hospital outsourcing contracts deliver steady, high-volume lab work from long-term agreements with public and private hospitals, generating predictable cash flow—SYNLAB reported €2.9bn revenue in 2024, with core diagnostics largely from hospital contracts.\u003c\/p\u003e\n\u003cp\u003eIn mature markets like Germany, France and Spain SYNLAB holds very high market share for basic hospital diagnostics (top-3 in Germany), requiring minimal promotion and enabling free cash flow to service corporate debt; 2024 adjusted EBITDA margin was about 15%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvironmental and Water Testing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe environmental and water testing division sits in a mature regulatory market with steady demand for soil, water, and air analysis; in 2024 SYNLAB (SYNLAB AG) reported group revenues ~3.9 billion EUR and environmental services contributed an estimated 5–8% of revenues, providing predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eAs a market leader, SYNLAB benefits from economies of scale and long-term industrial contracts; lab utilization rates often exceed 70% and gross margins for testing services run near 30–35%, making it a high-efficiency cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOccupational Health and Toxicology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSYNLAB’s Occupational Health and Toxicology is a cash cow: workplace drug testing and employee health screening serve a loyal corporate client base across Germany and France, with market maturity and FY2024 test volumes ~2.1 million and annual revenue ~€140m in this segment, yielding high margins.\u003c\/p\u003e\n\u003cp\u003eReputation for accuracy secures a defensive market share (~40% in Germany, ~35% in France), hard for new entrants to disrupt; low capital intensity means most revenue converts to free cash flow (estimated FCF margin ~25% in 2024).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished services: workplace drug testing, employee health screening\u003c\/li\u003e\n\u003cli\u003eGeography: Germany \u0026amp; France; test volumes ~2.1m (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue: ~€140m (2024); FCF margin ~25%\u003c\/li\u003e\n\u003cli\u003eMarket share: ~40% Germany, ~35% France; mature, defensive\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary Diagnostic Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSYNLAB’s Veterinary Diagnostic Services is a market-leading cash cow in pet and livestock diagnostics, with Europe’s veterinary diagnostics market valued at about €3.2bn in 2024 and SYNLAB holding a top-3 position in several markets, delivering predictable margins above group average (2024 EBIT margin ~18% in diagnostics segments).\u003c\/p\u003e\n\u003cp\u003eSteady demand for routine testing and herd health programs keeps volumes stable; growth is low-single digits, and capital needs are limited to maintenance and minor automation, so free cash flow conversion remains high.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size ~€3.2bn Europe 2024\u003c\/li\u003e\n\u003cli\u003eSYNLAB top-3 in multiple markets\u003c\/li\u003e\n\u003cli\u003eDiagnostics EBIT margin ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eGrowth low-single digits; high FCF conversion\u003c\/li\u003e\n\u003cli\u003eRequires mainly maintenance capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSteady diagnostics drive €3.9bn group revenue — 15% EBITDA, 25% cash conversion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoutine clinical diagnostics, occupational health, veterinary and environmental testing generated steady cash: ~40–45% group revenue, €3.9bn group revenue 2024, cash conversion ~25%, adjusted EBITDA margin ~15%, occupational test volumes ~2.1m (€140m), veterinary EBIT ~18%, environmental 5–8% of revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€3.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore diagnostics rev%\u003c\/td\u003e\n\u003ctd\u003e40–45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF margin\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcc. tests\u003c\/td\u003e\n\u003ctd\u003e2.1m (€140m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eSYNLAB BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact SYNLAB BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. It contains the same strategic quadrant mapping, market assumptions, and recommendations crafted by experts, so there are no surprises when you download. After purchase the clean, editable document is delivered instantly for printing, presenting, or integrating into your planning materials. This is the final product—ready to use. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748199936377,"sku":"synlab-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/synlab-bcg-matrix.png?v=1772206007","url":"https:\/\/growthsharematrix.com\/products\/synlab-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}